New Bipolar Disorder Study Shows that a Ketogenic Diet Leads to Mental and Physical Health Benefits
First-of-its-Kind European Pilot Study Shows Improvement in Mood, Energy, and Anxiety—Fueling Hope for a New Mental Health Treatment
Baszucki Group today announced a new pilot study on a ketogenic diet in bipolar disorder. “For the first time in years, I felt like my brain was finally running on the right fuel,” said one of the study participants. Published today in BJPsych Open, the study is the first to use neuroimaging to demonstrate that a ketogenic diet may improve brain metabolism in individuals with a bipolar disorder diagnosis. With over 100 years of evidence of efficacy in epilepsy, a ketogenic diet is now being studied around the world for a variety of psychiatric and neurological conditions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211683582/en/
The first-of-its-kind European study, supported by Baszucki Group, used advanced brain imaging techniques, including magnetic resonance spectroscopy (MRS), to measure changes in brain metabolism. The imaging revealed reductions in excitatory neurotransmitters typically elevated in bipolar disorder, suggesting a potential mechanism behind a ketogenic diet's effectiveness. The study also showed that ketone levels correlated with symptom improvement in a subset of individuals who reported daily ratings. This pilot trial points to an important new direction for research and offers hope for innovative treatment options for individuals living with this serious mental illness.
Co-led by University of Edinburgh scientists Iain Campbell, PhD, a Baszucki Metabolic Psychiatry Research Fellow, Daniel Smith, MD, FRCPsych, Chair of Psychiatry, and Harry Campbell, MD, FRSE, FMedSci, the research team enrolled 27 participants with bipolar disorder into a 6-8 week pilot trial of a ketogenic diet. Twenty participants completed the study, demonstrating that the intervention was safe and tolerable in this population. Most reached and maintained ketosis, with 91% of readings positive for blood ketones. Among participants who provided reliable daily ketone and mental health data assessments, increased ketone level was correlated with improvements in mood, energy, impulsivity, and anxiety, with some describing the intervention as life-changing.
“A ketogenic diet gave me a lifeline, restoring my energy and sense of hope,” said a study participant. “I felt like I was finally healing my mind, not just managing my bipolar symptoms. It opened me up to new possibilities and a brighter future.”
“Using a ketogenic diet is like giving my mind a warm bath,” said another participant. “The edginess is gone. I feel calmer, clearer, and my brain is working again.”
Markers of metabolic function also improved. Nineteen of 20 participants lost an average of 9.3 pounds (4.2kg) and saw improvements in body mass index (BMI) and blood pressure. These findings suggest that a ketogenic diet may help mitigate common metabolic health risks associated with bipolar disorder and its pharmacological treatments, which can lead to shortened life spans.
“We observed markers of reduced excitotoxicity in two key brain areas: the anterior cingulate cortex and posterior cingulate cortex—both implicated in bipolar disorder. We also observed effects on a marker which has been associated with Lithium and insulin signaling in the posterior cingulate cortex ” said Dr. Iain Campbell, who also lives with the disorder and follows a ketogenic diet to alleviate his symptoms. “These results add to a small but growing body of evidence suggesting that a ketogenic diet may be an effective adjunctive metabolic intervention for bipolar disorder. There is an urgent need for larger replication studies and carefully designed randomized clinical trials to build on these findings."
These changes align with the metabolic overdrive hypothesis, a theory Drs. Campbell have proposed, which posits that energy dysregulation is central to the mechanism of bipolar disorder and that addressing this dysregulation may be key to the success of ketogenic diet therapy.
A New Frontier in Mental Health
This pilot study paved the way for a broader initiative at the University of Edinburgh, made possible by a competitive research grant from the UKRI Medical Research Council that established the first European Metabolic Psychiatry Hub. The hub, to which Baszucki Group also contributed funding, is a collaboration of over 100 scientists dedicated to accelerating research into the connections between metabolism and mental health. Its focus is to explore the potential of ketogenic therapy and other metabolic interventions for treating severe mental illnesses.
This study is the second recently published pilot trial to demonstrate the safety and potential efficacy of ketogenic therapy in improving both metabolic and mental health markers in serious mental illness. The first trial, also funded by Baszucki Group, was conducted at Stanford University and also suggested that systemic metabolic changes from a ketogenic diet may help stabilize the brain in serious mental illness.
“This trial is another important step forward in establishing ketogenic therapy as a standard treatment for serious mental illness,” said Jan Ellison Baszucki, co-founder and President of Baszucki Group. “We’re proud to have supported this research and remain hopeful that ongoing studies will continue to advance our understanding of the metabolic intervention that saved our son’s life.”
As awareness grows about the deep connection between metabolic function and brain health, this study advances the global scientific movement toward neurometabolic approaches to understanding and treating mental illness.
About Baszucki Group
Launched in 2021 by Roblox founder and Chief Executive Officer David Baszucki and best-selling author Jan Ellison Baszucki, Baszucki Group leverages private giving, impact investing, advocacy, storytelling and community building to drive foundational change. A primary objective of Baszucki Group is to transform mental health outcomes by supporting initiatives at the intersection of metabolism, psychiatry, and neuroscience. To learn more about metabolic approaches to mental disorders, including ketogenic therapy, visit Metabolic Mind, a nonprofit initiative of Baszucki Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250211683582/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 04:12:00 CEST | Press release
Results at a glance:71.4% of MetaXplore™ reports from 4,616 patients identified actionable results41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often g
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 04:00:00 CEST | Press release
Optimizing Global Websites for the Japanese Visitors: Detailed UX/UI Adaptation, Comprehensive Japanese Localization, Extensive Localization and Cultural Relevance to Fit the Local Audience. Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 03:11:00 CEST | Press release
Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 114.5.2025 23:03:00 CEST | Press release
–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated–Oveporexton Found to be Generally Safe and Well Tolerated–Phase 3 Readout of Oveporexton Anticipated in 2025 Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo thro
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 22:05:00 CEST | Press release
Data across 31 abstracts illustrate BeiGene’s deep commitment to transforming treatment for B-cell malignanciesFour oral presentations highlight updated data from investigational BTK protein degrader BGB-16673 and BCL2 inhibitor sonrotoclax across a range of B-cell malignancies BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation scie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom